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Aim: The hepatitis B virus (HBV) is an important healthcare problem. Chronic hepatitis B infection may present with a wide range
of manifestations from inactive carrier state to cirrhosis and hepatocellular cancer. Therefore, treatment is very important in chronic
hepatitis B. In this study, the treatment results of 199 chronic hepatitis B patients taking entecavir 0.5 mg/day for 48 weeks were evaluated.
Materials and methods: This study retrospectively evaluated data of 199 treatment-naive chronic hepatitis B patients who were treated
with entecavir.
Results: Of the 199 treatment-naive chronic hepatitis B patients, 141 (70.9%) were males and 58 (29.1%) were females, and mean age of
the whole group was 37.5 ± 12.1 years. HBeAg was positive in 91 (45.7%) and antiHBe was positive in 108 (54.3%) patients. Mean HBV
DNA value was 666,449,365.5 ± 2,759,013,996.9 IU/mL, mean ALT value was 112.1 ± 95.7 U/L, and mean AST value was 95.3 ± 71.2
U/L. At week 24 of the treatment, HBV DNA levels were below 50 IU/mL in 56% of the HBeAg-positive and 76% of the HBeAg-negative
patients. At week 48 of the treatment, HBV DNA levels were below 50 IU/mL in 79% of the HBeAg-positive and 87% of the HBeAgnegative patients. At week 24, ALT had normalized in 72% of the HBeAg-positive and 79% of the HBeAg-negative patients. At week 48,
ALT had normalized in 89% of the HBeAg-positive and 88% of the HBeAg-negative patients. AntiHBe seroconversion was seen in 2 of
91 patients (2.2%), but the loss of HBsAg was never observed.
Conclusion: The 48-week entecavir treatment at a dose of 0.5 mg/day was shown to be effective both for HBeAg-positive and negative
patients.
Key words: Chronic hepatitis B, entecavir, entecavir efficacy

1. Introduction
Hepatitis B virus (HBV) infections are prevalent in both
Turkey and the rest of the world, and chronic hepatitis is
the leading chronic viral disease (1,2). Chronic hepatitis B
infections may present a wide range of manifestations from
the inactive carrier state to cirrhosis and hepatocellular
cancer (HCC) (3).
The goals of treatment for CHB are to permanently
suppress HBV replication and to relieve hepatic damage.
The ultimate target of treatment is the prevention
of cirrhosis and hepatocellular cancer (HCC) (4–6).
ALT normalization, HBV DNA clearance, HBeAg
seroconversion, and improved liver histology may be seen
during treatment (7,8).
Entecavir, which is a potent drug recommended
in the American Association for the Study of Liver
* Correspondence: serapdr@yahoo.com

Disease (AASLD) and the European Association for the
Study of the Liver (EASL) guidelines, was first used for
CHB after approval in the US in 2005 and in Turkey in
2007. It is a 2-deoxyguanosine analog, and after triple
phosphorylation by the host’s cellular kinases it forms
entecavir phosphate (ETV-TP). Its half-life is 15 h,
similar to lamivudine. ETV-TP inhibits HBV replication
in 3 separate steps, which differentiates it from other
nucleoside or nucleotide analogs. These steps are
inhibition of HBV-DNA polymerase primers, inhibition
of negative strand reverse transcription from pregenomic
RNA of HBV-DNA, and inhibition of HBV-DNA positive
strand synthesis. Triple-step inhibition of HBV highly
suppresses HBV-DNA, and in vitro studies showed that
entecavir is a stronger antiviral agent than lamivudine
and adefovir (4,6,9).
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In our literature review, there were no other studies
covering such a high number of patients in this country.
In this study, the data of 199 CHB patients treated with
0.5 mg/day of entecavir for 48 weeks were retrospectively
evaluated.
2. Materials and methods
This study retrospectively evaluated 199 treatment-naive
chronic hepatitis patients who were treated with entecavir.
This study was approved by the local ethics committee.
Biopsies were performed as suggested by AASLD
criteria. After marking via hepatic ultrasonography, the
biopsy was performed with a 16G Hepafix or Tru-cut
liver biopsy needle. Samples were sent to the pathology
laboratory immersed in a formaldehyde solution.
Entecavir 0.5 mg/day was started in patients with chronic
hepatitis B in accordance with the Turkish public health
system. Patient inclusion criteria were: having no previous
treatment for chronic hepatitis B; being over 18 years
old; having no compensated or decompensated cirrhosis;
having no contraindication for liver biopsy; and those who
were not pregnant or breastfeeding.
Before treatment, patients’ age, sex, address, phone
number, body mass index, occupation, family history,
underlying illnesses, symptoms, physical examination
findings, laboratory values (thrombocyte, leukocyte,
hemoglobin, prothrombin time (PT)), activated partial
thromboplastin time (APTT), HBsAg, antiHBs, HBeAg,
antiHBe, antiHCV, antiHDV, HBV DNA, ALT, AST,
albumin, creatinine, alpha fetoprotein (AFP), radiologic
findings (upper abdominal ultrasonography), pathology
results (Ishak score, a modified Knodell score, from liver
biopsy), and treatment protocols were recorded in patient
charts. Clinical complaints, physical examination findings,
and laboratory findings (HBV DNA, ALT, AST, and
creatinine) during follow-up visits were also recorded on
the same chart. Patients were thoroughly evaluated again
at the end of week 48, and symptoms, physical examination
findings, laboratory values (hemoglobin, PT, APTT,
HBsAg, antiHBs, HBeAg, antiHBe, antiHCV, antiHDV,
HBV DNA, ALT, AST, albumin, creatinine, phosphate,
calcium, ALP, and AFP), and radiologic findings (upper
abdominal ultrasonography) were also recorded in the
follow-up form.
During the treatment, HBV DNA, ALT, AST, and
creatinine values were measured at weeks 4, 12, 24, and
48 and were recorded in patient charts. Data were entered
in the SPSS 16.0 software. Categorical data were analyzed
by chi-square test, and continuous variables were analyzed
by t test and Mann–Whitney U test. To analyze repeated
measures, the analysis of variance of repeated measures test
was used, and significant results in this test were analyzed
by signed rank test. P < 0.05 was considered statistically
significant.
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3. Results
Of 199 treatment-naive chronic hepatitis B patients, 141
(70.9%) were males and 58 (29.1%) were females. The
mean age of the general group was 37.5 ± 12.1. Family
history was positive in 155 (77.9%) patients (Table 1).
HBeAg was positive in 91 (45.7%) and antiHBe was
positive in 108 (54.3%) patients. Mean HBV DNA value
was 666,449,365.5 ± 2,759,013,996.9 IU/mL, mean ALT
value was 112.1 ± 95.7 U/L, and mean AST value was 95.3
± 71.2 U/L (Table 2).
During follow-up visits, ALT and HBV DNA values
had markedly decreased, and this decrease was statistically
significant (P value 0.001 and 0.001, respectively) (Table
3).
In our study, HBV DNA values decreased at each
follow-up visit at weeks 0, 4, 12, 24, and 48 after entecavir
0.5 mg/day, and this decrease was statistically significant
(P = 0.01). The values of HBV DNA at weeks 4, 12, 24, and
48 were significantly lower than values at the treatment’s
start (P values were 0.01 for all) (Table 3). Additionally,
HBV DNA values at the weeks following treatment courses
were significantly lower than the values at weeks before
treatment courses (P values were 0.02 for all). At week
24, HBV DNA was below 50 IU/mL in 56% of HBeAgpositive and 76% of HBeAg-negative patients. At week 48
of treatment, HBV DNA was below 50 IU/mL in 79% of
HBeAg-positive and 87% of HBeAg-negative patients.
ALT values decreased both in HBeAg-positive and
negative patients at each follow up visit at weeks 0, 4, 12,
24, and 48 after entecavir 0.5 mg/day, and this decrease was
statistically significant (P = 0.001). Values of ALT at weeks
4, 12, 24, and 48 were significantly lower than values at the
Table 1. Demographic features of the patients.
Number

Percent (%)

Male

141

70.9

Female

58

29.1

0–18.0

5

2.5

18.1–25

138

69.3

25.1–30.0

56

28.1

Yes

155

77.8

No

44

22.2

Sex

BMI

Family History

(BMI: Body Mass Index)
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Table 2. Patients’ laboratory parameters and liver biopsy results (Ishak score, a modified
Knodell score).
Laboratory test

Result

ALT (0–40 U/L)

112.1 ± 95.7 U/L

AST (0–40 U/L)

95.3 ± 71.2 U/L

HBV DNA(<20 IU/mL)

666,449,365.5 ± 2,759,013,996.9 IU/mL

HBeAg positivity

45.7%

antiHBe positivity

53.8%

AFP (ng/mL)(0–8 ng/mL)

3.4 ± 2.1 ng/mL

Albumin (3.5–5.5 g/dL)

3.8 ± 0.3 g/dL

Thrombocytes (150,000–400,000/µL)

249,314.6 ± 97,377.5/µL

Table 3. HBV DNA and ALT values at follow-up visits.
Week 0

Week 4

Week 12

Week 24

Week 48

P value

HBV DNA (IU/mL)

666,449,365.5 ±
2,759,013,996.9

1,561,393 ±
6,897,102

51,094 ±
230,003

4641 ±
25,189

455 ± 1724

0.001

ALT(0–40 U/L)

112 ± 95

62 ± 35

41 ± 16

34 ± 13

28 ± 10

0.001

start of the treatment (P values < 0.01 for all). Moreover,
ALT values for the weeks following treatment courses were
significantly lower than the values for the weeks before
treatment courses (P values were 0.01 for all) (Table 3). By
week 24, ALT had normalized in 72% of HBeAg-positive
and 79% of HBeAg-negative patients (P = 0.310). By week
48, ALT had normalized in 89% of HBeAg-positive and
88% of HBeAg-negative patients (P = 0.818). At week 48 of
treatment, mean ALT value was 28 U/L (range of 13–77).
AntiHBe seroconversion was seen in 2 of 91 patients
(2.2%), but loss of HBsAg was never observed.
Patients tolerated the drug well. Nausea was reported by
12 (6%), abdominal pain by 5 (2.5%), diarrhea by 5 (2.5%),
and headache by 4 (2%) patients. No other side effects were
observed. None of the side effects were significant enough
to warrant discontinuation of the treatment.
4. Discussion
Virologic response in chronic hepatitis B treatment is
defined as a decrease in HBV DNA to values undetectable
by PCR and a loss of HBeAg in patients who were HBeAg
positive at the beginning of the treatment (4). Chang et al.
(10) measured HBV DNA levels below 300 copy/mL in 236
of 354 patients (67%) at week 48. Zheng et al. (11) followed
66 HBeAg-positive patients treated with entecavir 0.5 mg/
day for 24 months. Plasma HBV levels below 500 copy/mL

were regarded as undetectable. HBV DNA level decreased
to undetectable levels in 23 (34.8%) patients at week 12
of treatment and in 38 patients (57.6%) at week 24 of
treatment. Köklü et al. (17) obtained a virologic response
in 92.6% of the patients. We found that in HBeAg-positive
and negative patients, with 48 weeks of entecavir 0.5 mg/
day treatment, HBV DNA levels decreased at each followup visit at weeks 0, 4, 12, 24, and 48. This decline was
statistically significant. By week 24, HBV DNA levels were
below 50 IU/mL in 56% of HBeAg-positive and 76% of
HBeAg-negative patients. By week 48, HBV DNA levels
were below 50 IU/mL in 79% of HBeAg-positive and
87% of HBeAg-negative patients. Our results were in
concordance with the studies by Song et al. (12) and Zheng
et al. (11) (Table 4).
AASLD guidelines define a biochemical response as a
decrease in plasma ALT to normal levels (4). Gish et al.
(16) found that, after 48 weeks of entecavir treatment,
ALT normalized in 161 of 243 (66%) patients. Chang et
al. (10) measured ALT levels was within normal limits in
242 of 354 (68.3%) patients at week 48. Zheng et al. (11)
measured ALT levels within normal limits in 66 of 49
(74.2%) patients by week 24. Köklü et al. found the rate
of ALT normalization by week 48 to be 84.7%. We found
that ALT levels significantly decreased at each visit on
weeks 0, 4, 12, 24, and 48. By week 24 of treatment, ALT
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Table 4. Treatment response parameters at week 48.
HBeAg-positive patients
Lok and
McMahon
(4)

Chang
et al.
(10)

HBeAg-negative patients
Song
et al.
(12)

Buti
et al.
(13)

Chen
et al.
(14)

Kwon
et al.
(15)

Gish
et al.
(16)

76.1%

61%

62.5%

55.8%

64.1%

HBV DNA
negativity

67%

Normalization
of ALT

68%

HBeAg loss

22%

22%

26%

Anti HBe
seroconversion

21%

21%

22%

78%

had normalized in 72% of HBeAg-positive and 79% of
HBeAg-negative patients. By week 48 of treatment, ALT
had normalized in 89% of HBeAg-positive and 88% of
HBeAg-negative patients. The mean ALT level at week 48
was 26 U/L (range of 13–77) (Table 4).
The HBeAg loss/seroconversion rate was 23.5% in
a multicentric study conducted by Köklü et al. (17).
However, the lack of patients with HBeAg is noteworthy.
We found antiHBe seroconversion in 2 (2.2%) of 91
patients after 48 weeks of treatment with entecavir 0.5 mg/
day. The antiHBe seroconversion rates were higher in the
literature (4,10,13). However, there have been no reported
antiHBe seroconversion rates in Turkey, except the rates
published by Köklü et al. (17). The lack of seroconversion
rates in our study was related to genotype-D dominance
in this country (Table 4). Treatment was continued in 2
patients 1 year after the antiHBe seroconversion.
The ideal result of treatment is HBsAg loss, which is
frequently achievable with the currently available antiHBV agents (6). Lok and McMahon (4) found that a loss
of HBsAg was detected in 2% of patients. Chang et al.
(10) found HBsAg loss in 7 (2%) of 354 patients taking
entecavir at week 48 of treatment. Köklü et al. (17) did not
observe HBsAg loss. We did not observe HBsAg loss in
any of the patients in the current study.

Our
study

89%

Lok and
McMahon
(4)

Song
et al.
(12)

Buti
et al. (
13)

Chen
et al.
(14)

Our
study

90%

95%

92%

75%

87%

78%

83%

88%

23.5%

2.2%

Entecavir use has been associated with side effects
such as mild headache, upper respiratory tract infection,
cough, pharyngitis, malaise, upper abdominal pain, and
gastrointestinal discomfort (18). Chang et al. (10) reported
that common side effects in patients using entecavir were
mild to moderate degree headache, upper respiratory
tract infection, nasopharyngitis, cough, malaise, upper
abdominal pain, and diarrhea. None of these side effects
was seen in 306 of 354 (86%) patients. Gish et al. (16)
detected fatigue in 6% and headache in 10% of patients.
Zheng et al. (11) observed that patients tolerated entecavir
well. They detected upper respiratory tract infection
in 6 (9.1%), fatigue in 5 (7.6%), diarrhea in 2 (3%), and
cough in 1 (1.5%) of 66 patients. All of these side effects
were mild to moderate in severity. In our study, we also
observed that patients tolerated the drug well. We detected
nausea in 12 (6%), abdominal pain in 5 (2.5%), diarrhea in
5 (2.5%), and flatulence in 4 (2%) of 199 patients. We did
not observe any side effects other than those mentioned.
None of the side effects were serious enough to warrant
discontinuation of treatment.
In conclusion, good patient compliance, few side
effects, and efficiency in suppressing the infection are the
advantages of entecavir. Therefore, entecavir, which is one
of the most potent agents for CHB treatment, seems to be
effective and safe.
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